Table 1 Baseline demographics and disease characteristics in the intent-to-treat population
Characteristics | Number of cases (%) |
|---|---|
Age | |
Median, years (range) | 54 (33–77) |
< 60 | 29 (64.4) |
≥ 60 | 16 (35.6) |
Sex | |
Male | 32 (71) |
Female | 13 (29) |
ECOG performance score | |
0–1 | 43 (96) |
2 | 2 (4) |
Ann Arbor stage at diagnosis | |
III | 11 (24) |
IV | 34 (76) |
LDH | |
Within normal range | 35 (78) |
Elevated | 7 (16) |
Unchecked | 3 (7) |
B symptomsa | |
Absent | 38 (84) |
Present | 7 (16) |
BM involvement | |
Absent | 34 (76) |
Present | 11 (24) |
Histology | |
Nodal MZL | 15 (33) |
MZL of MALT-type | 30 (67) |
Lung | 8 (18) |
Ocular and adnexa | 6 (13) |
Stomach | 4 (9) |
Bone | 2 (4) |
Nasopharynx | 2 (4) |
Multiple MALT sites | 3 (7) |
Othersb | 5 (11) |
IPI score | |
1 | 13 (29) |
2 | 21 (47) |
3 | 9 (20) |
4 | 2 (4) |
Response to prior R–CVP | |
CR | 20 (44) |
PR | 22 (49) |
SD | 3 (7) |
No. first line R–CVP (6 cycles) | 10 (22) |
Treatment cycles (8 cycles) | 35 (78) |